West Midlands Genomic Medicine Centre (WMGMC) is hosting a free public event at Queen Elizabeth Hospital Birmingham (QEHB) examining the impact of genetics and genomic medicine on our understanding and treatment of cancer now, and in the future.
Entitled The Future of Cancer Treatment: Can genetic science benefit patients?, the evening is being organised in collaboration with the S:CORT Consortium – a Medical Research Council and Cancer Research UK-funded body which aims to use genome-based technology to personalise care for bowel cancer patients.
“Genetics and genomic medicine is set to transform our understanding of cancer,” said Professor Dion Morton, Director of the WMGMC and a colorectal surgeon at QEHB. “It will lead to improved diagnosis, personalised treatment based upon the patient’s own genetic make-up and new drugs therapies.
“This free event will give patients, the public and those interested in cancer care a great opportunity to hear about how this cutting-edge science is shaping treatment for patients in Birmingham, the West Midlands and beyond.”
The event will run from 6-9pm on Tuesday, March 28, in the Education Centre at QEHB, where those attending will hear from leading researchers and clinicians about cancer in NHS England’s pioneering 100,000 Genomes Project as well as the S:CORT programme and how genomics can improve bowel cancer therapies.
There will also be perspectives from patients and charities on the role of genomics in cancer care, a debate and a Q&A session.
The evening is being supported by Cancer Research UK and the Collaboration for Leadership in Applied Health Research and Care (CLAHRC) West Midlands.
Attendance is free but spaces are limited, so please register promptly at https://the-future-of-cancer-treatment.eventbrite.co.uk, e-mail email@example.com or call Becky Parke on 0121 371 5397.